Clinical trials: High-dose Chemotherapy
Breast Cancer
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002837
- Testing
- Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation
First randomization: After inclusion Use of Daunorubicin (arm D) or Idarubicin (arm I) as anthracyclin during all courses of chemotherapy (induction, consolidation courses before ASCT) Second randomization: After achieving 1st…
- Trial name
- AML2001 (NCT01015196)
- Testing
- Zavedos, Cerubidine
- Where
- France
- Volunteers
- 832 people
- Sponsor
- Nantes University Hospital
Lung Cancer
Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet
This study is conducted to test the hypothesis that patients with lung cancer undergoing treatment with immunotherapy, chemotherapy and tyrosine Kinase Inhibitors receiving a high protein diet and supplemented with fish oil will…
- Trial name
- NCT04965129
- Testing
- Fish oil
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Acute Myeloid Leukemia
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of…
- Trial name
- NCT04914676
- Testing
- Cytarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Florida
Mucositis Oral
Oral Self Care Protocol and Oral Mucositis
Objective: This study was conducted in order to examine the effect of oral self-care protocol based on Orem's Self-Care Deficiency Theory on oral mucositis and self-care agency.
- Trial name
- OSCP and OM (NCT06049511)
- Testing
- oral self care protocol, standard care
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ege University
Breast Cancer
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00002836
- Testing
- Filgrastim (G-CSF), Carmustine, Cisplatin
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00004188
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 96 sites in United States, Canada
- Volunteers
- 495 people
- Sponsor
- Children's Oncology Group
Osteosarcoma
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
The goal of this clinical research study is to learn if giving certain combinations of chemotherapy drugs before and after surgery, mostly in the outpatient clinic instead of in the hospital, can result in fewer hospital stays…
- Trial name
- NCT00673179
- Testing
- Doxorubicin, Cisplatin, Methotrexate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Breast Neoplasms
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
This is a pilot feasibility trial of AC (Adriamycin, cyclophosphamide) chemotherapy with G-CSF (filgrastim) followed by infusional Taxol (paclitaxel) as adjuvant treatment for patients with high risk stage II and stage III breast…
- Trial name
- NCT00001384
- Testing
- Adriamycin, cyclophosphamide, G-CSF
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
High Dose PET/CT-guided Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer
To assess the efficacy and feasibility of high-dose intensity-modulated radiotherapy with concurrent weekly paclitaxel and cisplatin for patients with locaregionally esophageal cancer
- Trial name
- NCT03936179
- Testing
- high dose radiation therapy with concurrent chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
This study will take place in parts: Dose Escalation (Part 1): Participants receive milademetan alone with different dose schedules Dose Escalation (Part 1A): Participants receive milademetan in combination with 5-azacytidine…
- Trial name
- NCT02319369
- Testing
- Milademetan, AZA
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Daiichi Sankyo
Lymphoma, Small Intestine Cancer
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
RATIONALE: Giving chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00669812
- Testing
- carmustine, cyclophosphamide, cytarabine
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002631
- Testing
- chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Radiation Therapy Oncology Group
Hodgkin Lymphoma
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or…
- Trial name
- NCT01022996
- Testing
- Everolimus (RAD001)
- Where
- 16 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Germ Cell Tumor
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed…
- Trial name
- NCT06937866
- Testing
- Zanzalintinib, Etoposide Capsule
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Indiana University
Brain and Central Nervous System Tumors
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00820963
- Testing
- temozolomide, hypofractionated radiation therapy, radiation therapy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard
Lymphoma, B Cell
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central…
- Trial name
- NCT00210314
- Testing
- high dose methotrexate, high dose cytarabine, radiotherapy
- Where
- Switzerland
- Volunteers
- 79 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Multiple Myeloma
Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Complete Response (CR) plus near CR rate of VAD (Vincristine, Adriamycin, Dexamethasone) induction chemotherapy followed by ASCT in patients with newly diagnosed MM was about 50% and CR plus near CR rate of PAD (Bortezomib…
- Trial name
- NCT01255514
- Testing
- high dose dexamethsone
- Where
- 8 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Cancer, Anemia
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
The purpose of this study is to determine the effectiveness and safety of PROCRIT (Epoetin alfa) at a starting dose of 60,000 Units (U) once every week (QW) to a target hemoglobin (Hb) of 12 g/dL (Initiation Phase), followed by a…
- Trial name
- NCT00338416
- Testing
- Epoetin alfa
- Volunteers
- 115 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Autoimmune Diseases
Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases
While glucocorticoids and immunosuppressants ameliorate manifestations of autoimmune diseases in many patients, current therapies are insufficient to control the disease in a subset of patients, and their clinical prognosis…
- Trial name
- ASTRAD (NCT00742300)
- Testing
- Autologous hematopoietic stem cell transplantation
- Where
- Germany
- Sponsor
- Charite University, Berlin, Germany